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Polycystic livers are seen in the rare inherited disorder isolated
polycystic liver disease (PCLD) and are recognized as the most
common extrarenal manifestation in autosomal dominant poly-
cystic kidney disease. Hepatic cystogenesis is characterized by
progressive proliferation of cholangiocytes, ultimately causing
hepatomegaly. Genetically, polycystic liver disease is a hetero-
geneous disorder with incomplete penetrance and caused by muta-
tions in PRKCSH, SEC63, PKD1, or PKD2. Genome-wide SNP typing
and Sanger sequencing revealed no pathogenic variants in hith-
erto genes in an extended PCLD family. We performed whole-
exome sequencing of DNA samples from two members. A hetero-
zygous variant c.3562C > T located at a highly conserved amino
acid position (p.R1188W) in the low density lipoprotein receptor-
related protein 5 (LRP5) gene segregated with the disease (loga-
rithm of odds score, 4.62) but was not observed in more than 1,000
unaffected individuals. Screening of LRP5 in a PCLD cohort identified
three additional mutations in three unrelated families with polycys-
tic livers (p.V454M, p.R1529S, and p.D1551N), again all undetected in
controls. All variants were predicted to be damaging with profound
structural effects on LRP5 protein domains. Liver cyst tissue and
normal hepatic tissue samples from patients and controls showed
abundant LRP5 expression by immunohistochemistry. Functional ac-
tivity analyses indicated that mutant LRP5 led to reduced wingless
signal activation. In conclusion, we demonstrate that germ-line LRP5
missense mutations are associated with hepatic cystogenesis. The
findings presented in this study link the pathophysiology of PCLD
to deregulation of the canonical wingless signaling pathway.
gene identification | β-catenin pathway
Polycystic liver diseases (PLD) consist of a group of inheriteddisorders characterized by abnormal proliferation and differ-
entiation of the bile duct epithelium (1). Ductal plate malforma-
tion results in development of multiple fluid-filled cysts spread
throughout the liver parenchyma. Progressive hepatic cystogenesis
and cyst growth cause hepatomegaly and symptoms such as ab-
dominal distension and pain, pyrosis, anorexia, and dyspnea.
Congenital PLD are clinically heterogeneous, and two major
types can be distinguished. Autosomal dominant polycystic kidney
disease (ADPKD) is a potentially lethal condition afflicting about
1:400–1:1,000 persons in the United States (2). Patients may de-
velop end-stage renal disease resulting from polycystic kidneys,
and 83% have the simultaneous presence of multiple hepatic
cysts (3). Formal diagnostic criteria for ADPKD include age,
number of renal cysts for each kidney, and family history of
renal disease (4, 5). Isolated polycystic liver disease (PCLD)
shares the phenotype of a polycystic liver but is distinct from
ADPKD because renal disease is absent (6). Some patients
may, however, have sporadic renal cysts. Diagnosis of PCLD is
made by a family history consistent with autosomal dominant
inheritance and the presence of at least one (<40 y) or more than
three (>40 y) hepatic cysts (7).
The natural course of PCLD and ADPKD depends on a
spectrum of factors that include age, sex, anticonceptives, preg-
nancy, and mutation(s) (8–10). Classical linkage analysis has
identified four genes that underlie both inherited disorders. Muta-
tions in polycystic kidney disease 1 or 2 (PKD1 or PKD2) genes
(NM_601313 and NM_173910, respectively), which encode poly-
cystin-1 and polycystin-2, are responsible for almost all ADPKD
cases (11–13). Both proteins are located in the cilium and are im-
portant in renal tubular cell morphogenesis and signaling func-
tions, including the wingless (Wnt) signaling pathway (β-catenin
pathway). Mutations in protein kinase C substrate 80K-H (PRKCSH)
and Saccharomyces cerevisiae homolog 63 (SEC63) are linked to
PCLD (NM_002743.2 and NM_007214.4, respectively), and both
gene products are located to the endoplasmic reticulum and are
involved in processing and folding of glycosylated proteins (14–16).
In addition, the canonical Wnt signaling may be deregulated by the
interaction partner nucleoredoxin of the Sec63 protein during oxi-
dative stress (17). In contrast to ADPKD, only 25% of PCLD cases
can be explained by mutations in already known genes (18), indi-
cating that mutations in several other as yet unidentified genes are
involved in this disease. We hypothesized that another PCLD gene
is involved in an extended PCLD family negative for the known
disease genes and performed whole-exome sequencing. This unique
approach has proven to be successful for the identification of the
genetic cause of other Mendelian disorders (19–21).
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Extended Polycystic Liver Disease Family. We assessed a 49-y-old
female (III/18) by clinical history taking and physical and ra-
diological examination. She presented to us with a severe
symptomatic polycystic liver without renal cysts and complained
of abdominal distension, pain, dyspnea, and pyrosis. There was
no history of renal disease, hypertension, or intracranial aneur-
ysms. She used contraceptives for a total of 30 y and had two
pregnancies. CT scanning revealed numerous cysts with diame-
ters of 5–18 cm in liver segments I–III and VII. Despite aspi-
ration sclerotherapy and laparoscopic deroofing of the liver cysts,
her symptoms persisted, and she enrolled in a clinical trial for
long-acting octreotide treatment (22). We expanded our clinical
analysis and identified a 40-member Dutch family with three
generations of early- and late-onset cystogenesis inherited in an
autosomal dominant fashion (PCLD-1). Next, we studied 19
individuals with cystogenesis, of which 16 were affected with
a polycystic liver according to the Reynolds criteria (5, 7), and
three members were affected with renal cysts that came from the
40-member Dutch family (Fig. 1A). The proband (III/18)
possessed no pathogenic variants affecting any of the known
PCLD or ADPKD genes.
Whole-Exome Sequencing Identifies Pathogenic LRP5 Variant. We
performed exome sequencing on genomic DNA in two members
(III/18 and II/18) from the PCLD-1 family with an advanced
polycystic liver phenotype (Fig. 1B). Exome capture and se-
quencing were performed using the Agilent SureSelect target
enrichment system with SOLiD4 sequencing. We identified
24,178 and 25,332 genetic variants per proband, respectively
(Tables S1 and S2). Variants were annotated by a bioinformatics
pipeline as described previously (19, 20). Variant follow-up re-
quired the presence of at least five unique variant reads (dif-
ferent start sites), and the variant had to be present in at least
20–80% of all reads suggestive of heterozygous changes in
a dominant model of disease. Next, we prioritized variants based
on predicted amino acid consequences and overlap with com-
mon variation (presence in dbSNP v134 and/or an in-house
database containing 1,300 analyzed exomes of predominantly
European ancestry). We identified 11 unique nonsynonymous
variants present in both affected relatives (Table S3). All 11
variants were tested for segregation in both probands and all
other family members by Sanger sequencing. The only private
nonsynonymous variant that cosegregated completely with the
disease was a missense mutation (c.3562C > T with evolutionary
conserved amino acid change p.R1188W) located on chromo-
some 11q13.2 in the low-density lipoprotein receptor-related protein
5 (LRP5) gene (NM_002335.2; Fig. 1 C and D). We checked se-
quence coverage and excluded the presence of potential patho-
genic variants in the 2 Mb surrounding LRP5. All 19 individuals
with cystogenesis possessed LRP5 c.3562C > T (Table S4 and
Fig. S1). Analysis of the sequence data revealed linkage at the
LRP5 locus with the disease with a significant logarithm of odds
(LOD) score of 4.62 (Fig. S2). This LRP5 variant (c.3562C > T)
was not detected in genome-wide sequence data from the 1000
Genomes Project (23), 6,500 individuals from the National Heart,
Lung, and Blood Institute Exome Sequencing Project (24), or
exome data from 1,300 individuals of predominantly European
ancestry sequenced in-house (19, 20) and excluded by Sanger
sequencing in a control set of 1,000 Dutch DNAs of healthy,
unrelated individuals. This LRP5 mutation affected a highly
conserved amino acid and was predicted to be damaging by
PolyPhen-2, MutPred, and sorting intolerant from tolerant (SIFT)
models (Table 1).
LRP5 is a known disease gene causing severe skeletal bone or
retinal disorders and is associated with metabolic disease (Fig.
S3). Therefore, we actively investigated the possible presence of
subtle clinical signs in our family by slit-lamp eye examination.
These investigations excluded familial exudative vitreoretinop-
athy (FEVR) in any of the family members (SI Text). We
assessed bone density of the lumbar spine and left hip in 13
patients and 9 unaffected relatives. The lumbar T-score was
lower in LRP5 mutation carriers but within the normal range,
and no member had a bone density disorder. Routine laboratory
testing, including renal parameters, did not reveal differences
between individuals with and without the LRP5 mutation (Table
2). Therefore, other LRP5-related disorders were ruled out in
this index family.
Additional LRP5 Variants in Polycystic Liver Disease. To confirm our
results, we sequenced LRP5 in a cohort of 150 unrelated PCLD
probands without PRKCSH, SEC63, or PKD2 gene mutations.
We identified two additional PCLD families (one Dutch and one
Moroccan) and one Dutch PCLD singleton case with private
LRP5 missense variants. Mutations c.1360G > A (p.V454M) and
c.4587G > C (p.R1529S) segregated with the disease in both
families, and unaffected relatives of the singleton case (c.4651G >
A; p.D1551N) did not carry the mutation (Fig. S4).
Mutation c.1360G > A (p.V454M) was present in an 86-y-old
polycystic liver patient. Her mutation-positive daughter had
Fig. 1. Identification of LRP5 variants p.R1188W in an extended Dutch
PCLD-1 family (A) and three additional LRP5 variants in three unrelated PCLD
families. Generations are denoted with Roman numerals, and individuals are
numbered in a counterclockwise way. Squares indicate male sex, and circles
indicate female sex. Solid symbols denote affected individuals, and open
symbols are individuals without or unknown for PCLD. A slash indicates that
the individual is deceased. (B) Simplified pedigree from PCLD-1 family with
the clinical features by abdominal CT scanning and ultrasound of the liver of
both probands (III/18 and II/18) in which whole-exome sequencing was per-
formed (green arrow). (C) LRP5 is located at chromosome 11q13.2, and the
sequence electropherogram shows heterozygous germ-line mutations. (D)
All LRP5 missense mutations were located at highly evolutionary conserved
amino acid regions with ortholog proteins from human to frog.
5344 | www.pnas.org/cgi/doi/10.1073/pnas.1309438111 Cnossen et al.
several bilateral renal cysts and small hepatic cysts on CT scanning.
The daughter died as a result of a metastasized liposarcoma at the
age of 49. A 43-y-old Moroccan female had multiple dominant
hepatic cysts without renal disease. Her 71-y-old mother had
several hepatic cysts without renal cysts. Both carried the
c.4587G > C (p.R1529S) mutation in the LRP5 gene. A fourth
mutation [c.4651G > A (p.D1551N)] was present in a 65-y-old
male with a polycystic liver and three renal cysts. There was no
evidence for renal failure. The phenotype of his deceased
parents was unknown, and both his healthy children were
without hepatic or renal cysts and did not harbor the LRP5
mutation. None of the LRP5 variants were detected in chro-
mosomes from healthy unrelated and ethnically matched con-
trols (Dutch, n = 1,000; Moroccan, n = 525) nor were they
present in the in-house or online exome sequencing datasets. In
addition, all four LRP5 missense variants affected highly con-
served amino acids and again were predicted to be damaging or
deleterious by PolyPhen-2, MutPred, and SIFT (Table 1).
LRP5 Expression in Liver Cyst Tissues. LRP5 has a wide tissue dis-
tribution, including liver and kidney, and expression has been
reported in Kupffer cells, macrophages, stellate cells, chol-
angiocytes, and hepatocytes (25). In line with Northern blotting
experiments (26), we found abundant LRP5 protein presence in
normal liver tissues and relevant for PCLD. In the affected
proband (III/18), we observed intense LRP5 staining of cyst-lining
epithelium and bile ducts. The intensity of LRP5 expression was
comparable in cyst tissue sections derived from a PRKCSH mutant
and to bile duct epithelium (Fig. 2 A and B). This abundant LRP5
expression in cyst tissue indicates that there is no significant loss
of structural LRP5 protein from relevant tissue in LRP5 carriers.
For analysis of structural effects of the LRP5 variants, we gen-
erated separate models for these domains (Fig. 2 E and F and Table
S5) (27). The human LRP5 protein contains 1,615 amino acids
and includes a long extracellular region, a single-span trans-
membrane region, and a relatively short (208 amino acids) in-
tracellular region. The extracellular region consists of four
β-propeller domains with subsequent epidermal growth factor
(EGF)-like domains. Near the transmembrane region are three
LDL receptor class A repeats, whereas on the cytoplasmatic side,
five PPPSP motifs are present. The β-propeller domains all
consist of six segments of which most carry a characteristic
YWTD motif. Arginine 1188 creates hydrogen bonds and ionic
interactions in the core of the β-propeller structure, which is
predicted to be lost by the tryptophan mutation (p.R1188W).
Additionally, the larger tryptophan side-chain will cause steric
clashes, which will most likely disturb the whole β-propeller
domain. Valine 454 induces several hydrophobic interactions but
is also partly exposed to the solvent. Mutant methionine is pre-
dicted not to have major structural effects as both amino acids
are hydrophobic, and the methionine side-chain appears to fit at
this position (p.V454M). Both p.R1529S and p.D1551N muta-
tions are intracellularly located between PPPSP motifs, and an
intracellular homology model is absent.
Reduced Activation of Canonical Wnt Signaling. To identify the un-
derlying mechanism of mutated LRP5 on the Wnt pathway, we
conducted luciferase activity assays with LRP5WT, one extracellu-
larly (LRP5R1188W) and one intracellularly located (LRP5D1551N)
mutant, and an empty expression vector as a control. Immunoflu-
orescence imaging in WT and both mutant constructs presented
similar localization of LRP5 (Fig. 2 C and D). Western blots of the
cell lysates showed comparable protein expression of all constructs
(Fig. 2G). Overexpression of the LRP5 constructs in CHO cells
increased basal and Wnt3a-induced luciferase activity compared
with the empty vector (P < 0.0001). In the presence ofWnt3a, signal
Table 1. Summary and in silico analysis of four LRP5 variants in polycystic liver disease
Family ethnicity Mutation (c.DNA) NM_002335.2 Predicted effect on protein PolyPhen2 MutPred SIFT
PCLD-1 Caucasian (Dutch) c.3562C > T p.R1188W Probably damaging 1.00 0.552 Deleterious 0.00
PCLD-2 Caucasian (Dutch) c.1360G > A p.V454M Possibly damaging 0.872 0.520 Deleterious 0.01
PCLD-3 Moroccan c.4587G > C p.R1529S Possibly damaging 0.610 0.288 Deleterious 0.00
PCLD-4 Caucasian (Dutch) c.4651G > A p.D1551N Probably damaging 0.999 0.235 Deleterious 0.00
Table 2. Baseline characteristics of PCLD-1 family
Characteristics
No hepatic cystogenesis
and no LRP5 mutation (n = 9)
Hepatic cystogenesis and
LRP5 mutation (n = 13) P value
Age (y) 55 ± 12 56 ± 13 NS
Female sex, no. (%) 6 (67) 9 (69) NS
Bone density: Hip
T-score −0.19 ± 0.78 −0.08 ± 0.93 NS
Z-score 0.69 ± 0.68* 0.95 ± 0.94 NS
Bone density: L1-L2-L3-L4
T-score 1.18 ± 0.95* 0.19 ± 0.88 0.042
Z-score 1.81 ± 0.89* 1.18 ± 1.03 NS
Creatinin (μmol/L) 69 ± 14 73 ± 20 NS
Cholesterol (mmol/L) 5.39 ± 0.71 5.44 ± 1.01 NS
GFR (MDRD) (ml/min/1.73 m2) 87 ± 13 85 ± 25 NS
BMI (kg/m2) 25.7 ± 2.5 26.4 ± 5.2 NS
Triglycerides (mmol/L) 1.35 ± 0.71 1.80 ± 0.93 NS
HDL (mmol/L) 1.34 ± 0.40 1.38 ± 0.32 NS
LDL (mmol/L) 3.44 ± 0.82 3.25 ± 0.78 NS
Non HDL (mmol/L) 4.06 ± 0.93 4.07 ± 0.93 NS
HbA1C (%) 5.5 ± 0.6 5.7 ± 0.8 NS
HbA1C (mmol/mol) 37 ± 6 39 ± 9 NS
NS, not significant.
*There was one missing value because of degenerative abnormalities of the lumbar spine in an 85-y-old woman.











activation was significantly down-regulated by 30% and 45%, taking
into account the basal activity in both LRP5mutants compared with
the LRP5WT. We also detected a significant decreased (P < 0.001)
activity of LRP5 mutant p.D1551N without the presence of Wnt3a
(Fig. 2H). Luciferase activity assays were repeated in HEK293 and
human liver-derived H69 cells, where comparable significant results
were obtained (Fig. S5).
Altered Expression Levels of Wnt Target Genes. Subsequently, we
conducted quantitative PCR (qPCR) experiments of transducers
and transcription factors associated with the canonical Wnt
signaling. Our analyses show that HEK293 cells transfected with
mutant LRP5 led to altered expression levels of target genes
compared with LRP5WT (Fig. S6). There was a significant in-
creased gene expression of transducers adenomatous polyposis
coli, glycogen synthase kinase 3β (GSK3β), and leucine-rich
repeat-containing G-protein-coupled receptor 5 (LGR5) and tran-
scription factor v-myc avian myelocytomatosis viral oncogene
homolog (c-Myc) in LRP5R1188W or LRP5D1551N, compared with
LRP5WT. Similarly, axis inhibitor-1 (AXIN-1), axis inhibitor-2
(AXIN-2), lymphoid enhancer-binding factor 1 (LEF1), SRY-box 9
(SOX9), fibroblast growth factor 18 (FGF18), and cyclin D1 (CCND1)
were also up-regulated. In the presence of the extracellular regu-
lator Wnt3a, expression levels of several Wnt signaling components
changed (Fig. S7). Decreased expression levels were found for
GSK3β, AXIN-1, AXIN-2, LGR5, c-Myc, CCND1, and LEF1
compared with LRP5WT in both mutated LRP5 constructs. These
results are in line with the functional consequences of these LRP5
mutations as shown with luciferase activity assays (Figs. S8 and S9).
Discussion
This study identifies LRP5 as a novel gene associated with he-
patic cystogenesis in patients clinically diagnosed with PCLD.
The initial discovery was made in two affected relatives from an
extended Dutch family by exome sequencing (21). A private
missense mutation c.3562C > T (p.R1188W) in the LRP5 gene
segregated with 18 affected relatives (>40 y), with a significant
LOD score of 4.62. These findings are corroborated by the
presence of three additional private missense LRP5 variants in
two PCLD families and one PCLD singleton. All unique variants
identified in LRP5 affected highly conserved amino acids and
were predicted to be damaging or deleterious. The identification
of LRP5 as a causative gene follows that of PRKCSH (15%) and
SEC63 (6%) for isolated polycystic liver disease in a PCLD
cohort (18).
LRP5 is a single-span transmembrane protein that acts as
a coreceptor with Frizzled protein family members for trans-
ducing signals by Wnt proteins. Wnt signaling directs a number
of fundamental physiological mechanisms such as cell pro-
liferation, cell polarity, and cell fate determination during em-
bryonic development (28). Until now, LRP5 variants were linked
to a spectrum of Mendelian genetic diseases. LRP5-related dis-
orders include autosomal dominant conditions with abnormal
bone density, such as endosteal hyperostosis and osteosclerosis
(29–32), but also eye disorders such as recessive and dominant
forms of FEVR (29, 33, 34). Our findings expand the clinical
spectrum of LRP5-associated phenotypes because there were no
extrahepatic features in patients with LRP5 mutations in our
studies. Specifically metabolic disorders, diabetes mellitus, skel-
etal bone, and retinal diseases were absent in the index family,
and these were not reported for the other three families. We
performed specific clinical investigations in extended family 1
and excluded FEVR in individuals with LRP5 germ-line muta-
tions by slit-lamp eye examination. Bone density measurements
ruled out bone diseases in individuals with and without PCLD.
Hepatic or renal cystogenesis has not been observed in associa-
tion with FEVR or with bone diseases.
Why different LRP5 mutations can result in such a wide
spectrum of complex diseases that targets different tissues
remains to be determined. LRP5 is detected by Northern blot
analysis, immunohistochemistry, and in situ hybridization studies
in several tissues including the liver and kidney (25, 26). Until
now, LRP5 mutations were linked to pathological retina or bone
development. In the extended PCLD-1 family, we identified the
LRP5 c.3562C > T mutation in 22 individuals, of which 19 had
hepatic and/or renal cystogenesis. Two members were too young
(<40 y) to develop hepatic cysts, and one individual is an ex-
ample of incomplete penetrance. Indeed, there was considerable
clinical heterogeneity in affected members without complaints or
patients with severe abdominal discomfort in the PCLD-1 family.
This clinical heterogeneity has been described in families with
Fig. 2. Functional and structural analyses of LRP5 variants in polycystic liver
disease. (A) Immunohistochemistry of liver cyst tissue from proband III/18 of
PCLD-1 family with LRP5 mutation c.3562C > T (p.R1188W). The cyst lining
cholangiocytes present positive staining for LRP5 compared with the negative
control next. (B) PCLD patient with a PRKCSH c.1341–2A > G mutation shows
similar staining of liver cyst tissue and expression of LRP5 compared with A. (C)
Localization of LRP5 protein was analyzed by immunofluorescence microscopy.
CHO cells were transfected with constructs expressing LRP5WT, (D) LRP5R1188W,
or LRP5D1551N and compared with negative controls. No differences in LRP5
localization between all constructs was detected. (E) Presentation of the hu-
man LRP5 protein and homology modeling of the β-propeller domains high-
lighting the amino acid changes to emphasize the impact on the configuration
and surrounding protein domains. (F) Homology modeling of the LRP5
domains and detailed view of the amino acid changes shows extracellular LRP5
mutation (*indicated) p.R1188W located at the sixth blade of the fourth
β-propeller domain, and LRP5 mutation p.V454M at the third blade of the
second β-propeller domain. Both intracellular mutations p.R1529S and
p.D1551N are located between PPPSP motifs A and B and PPPSP motifs B and
C, respectively. (G) CHO cells were transiently transfected with empty, WT, or
mutant LRP5 vector. Whole cell lysate was analyzed by Western blotting using
the V5 antibody and anti–β-actin. LRP5 protein expression levels (normalized
to β-actin) are similar between LRP5WT and both mutant constructs LRP5R1188W
and LRP5D1551N. (H) Canonical Wnt signaling activity was analyzed by firefly
luciferase activity and normalized to renilla luciferase activity with (in gray) or
without addition of 250 ng/mLWnt3a. All LRP5 constructs showed a significant
increase inWnt signaling activity compared with the empty vector (P < 0.0001).
Both LRP5 mutants showed a decreased Wnt3a-induced signal activity (*P <
0.001; **P < 0.0001). Activity of LRP5D1551N without Wnt3a was significantly
decreased compared with LRP5WT.
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PRKCSH- and SEC63-associated PCLD (14, 18), and penetrance
of PRKCSH-associated PCLD is estimated at ∼80%. Intrafamilial
phenotypic variability suggests that modifier genes and/or envi-
ronmental factors play a major role in PCLD disease expression.
Similarly, the clinical expression of LRP5-associated bone and eye
diseases is highly variable (27).
There have been efforts to recapitulate the involvement of
LRP5 mutations in a number of bone and eye disorders in mice.
A targeted KO Lrp5tm1Jsak/Lrp5tm1Jsak mouse suffers from un-
specified hepatobiliary abnormalities that might implicate phe-
notypic overlap with our observed human phenotypes (35).
Human and mouse LRP5 share a high degree of amino acid
identity to coreceptor low density lipoprotein receptor-related
protein 6 (LRP6) and have a similar domain structure (36).
Furthermore, there has been speculation about functional re-
dundancy between both transmembrane coreceptors of the ca-
nonical Wnt signaling pathway (37). The homozygous KO Lrp6
mouse is embryonic lethal and possesses polycystic kidneys (37)
compatible with the ADPKD phenotype. There is further ex-
perimental data to suggest that renal cystogenesis in ADPKD is
linked to defective canonical Wnt signal transduction. Pertur-
bations of polycystins cause inappropriate levels of β-catenin,
and activation and inactivation of the Wnt signaling pathway are
reported in different polycystic kidney disease mice models
during embryonic or postnatal development (38–42). Our find-
ings provide a direct link between canonical Wnt signaling and
polycystic liver disease as Wnt signaling is reduced in mutant
LRP5 compared with WT LRP5. A moderate reduction of sig-
naling activity is in line with known LRP5 missense mutations in
retina and bone disorders (43, 44). These observations support
a role of an imbalanced canonical and noncanonical Wnt signal
transduction in the pathogenesis of LRP5-associated polycystic
diseases. We speculate that LRP5, along with other genes im-
plicated in hepatic cystogenesis, PKD1, PKD2, PRKCSH, and
SEC63, is part of the functional genetic network. Experimental
studies have observed that reduced dosage of these gene prod-
ucts, and in particular polycystin-1, is required to cause cyst
formation (45, 46).
The identification of LRP5 associated with hepatic cysto-
genesis affords a better understanding of the pathophysiology of
PCLD. Positivity for immunoreactive LRP5 in cyst epithelium
suggests that the protein is structurally intact. Functional assays
in three different cell systems indicate that the mutation renders
the protein to be less functional and that leads to inhibition of
the canonical Wnt signaling (41, 42).
In conclusion, PCLD is a genetically heterogeneous disorder
that may be caused by LRP5 gene mutations. Our results link
hepatic cystogenesis to dysregulated canonical Wnt signaling and
are in line with data that were generated from ADPKD models
(41, 42). Polycystins modulate Wnt signaling during organ de-
velopment and contribute to hepatic and renal cystogenesis
(42, 47, 48). Our study provides evidence that mutations in LRP5
are related to hepatic cyst development and fuels the hypothesis
that canonical Wnt signal transduction is important in polycystic
diseases. It is possible that disruption of other (downstream)
members of the Wnt signaling pathway may be associated with
initiation of hepatic and renal cyst formation.
Materials and Methods
Human Subjects. Ultrasound images of liver and kidneys were acquired using
a 3.6-MHz general purpose clinical echo system (Acuson ×150; SiemensAG)
equipped with a curved linear array transducer. Blood samples were collected
from all 40 subjects, and DNA was extracted from blood leukocytes using the
HP-PCR Template Preparation kit (Roche Applied Science). Formalin-fixed par-
affin-embedded liver cyst tissue specimens were available from proband III/18
after laparoscopic cyst fenestration. DNA samples from 1,000 Dutch and 525
Moroccan healthy unrelated individuals were used as controls. All subjects
provided written informed consent for all investigations. This study was ap-
proved by the Medical Ethics Committee of the Radboud university medical
center, The Netherlands.
Sanger Sequencing. PCR products of proband III/18 for all exons of the PRKCSH,
SEC63, PKD1, and PKD2 genes were analyzed by traditional Sanger sequencing
on ABI310 or ABI3100 Genetic Analyzers (Applied Biosystems). Complete se-
quence analysis for PKD1 variants was conducted by an experienced Center
(Bioscientia). Exon and exon-intron boundaries of LRP5 were determined
using the Genome Bioinformatics Group of University of California, Santa Cruz
(UCSC) Genome Browser, and unique primers were designed (Primer3). Het-
erozygous changes in LRP5 were detected by high-resolution melting curves
(RotorGene-Q; Qiagen) and validated by Sanger sequencing.
Genome-Wide Copy Number Variation Analysis. DNA from whole blood was
analyzed on the CytoScanHD, which contains 2.6 million probes (Affymetrix).
Hybridizations were performed according to the manufacturer’s protocol. Ge-
notype calls and copy number variation analysis were made using Affymetrix
Chromosome Analysis Suite v1.2.0.225.
Whole-Exome Sequencing. Exome enrichment was performed using the
SureSelect Human All Exon 50-Mb Kit (Agilent), covering ∼23,000 genes.
Emulsion PCR and bead preparation were made by using the EZbead system
according to the manufacturer’s instructions followed by SOLiD4 sequencing
(Life Technologies). Reads were mapped to the hg19 reference genome
using SOLiD Bioscope software v1.3 and annotated as described previously
(19, 20). All nonsynonymous variants shared in both affected individuals,
absent or with very low frequency in dbSNP, were tested and validated in
healthy and affected members of PCLD-1 family for cosegregation by high-
resolution melting curve analysis and Sanger sequencing.
Linkage Analysis. We calculated the two-point LOD score for linkage in the
extended family using the SuperLink-v1.6 program in EasyLinkage-v5.08 soft-
ware package. To determine the actual two-point LOD score for the LRP5
mutation that was detected in this family, the mutation was considered to be
a microsatellite marker in close proximity of LRP5 (D11S4117). An autosomal
dominant mode of inheritance was assumed with a penetrance of ∼80%, and
the disease allele frequency was estimated at 0.0001 (Fig. S2 and SI Text).
Clinical Investigations. Because LRP5 mutations are associated with bone
density disorder, metabolic, and ocular developmental diseases, we performed
additional clinical investigations of members from the PCLD-1 family with
a clear genotype-phenotype relation. An ophthalmologist (C.E.N.) performed
an eye examination by a slit lamp to exclude retinal disorders such as FEVR. At
the same time, we analyzed metabolic and renal parameters in blood from
these 22 individuals of the PCLD-1 family. We assessed bone density of the
lumbar spine and left hip by dual energy X-ray absorptiometry (DXA scan;
Hologic Discovery A). Results are reported as T- and Z-scores, which reflect the
number of SDs by which a patient’s value differs from the mean of a group of
young or age-matched normal controls, respectively.
In Silico Analysis and Homology Modeling.We used three computational tools
for the prediction of the functional effect of mutational variants (PolyPhen-2,
Mutpred, and SIFT). LRP5 protein structure was created by using an LRP6
template as a start homology model and reconstruction by the YASARA&
WHAT-IF Twinset. PDB files were available as templates for homology
modeling of WD40 domains (β-propeller subdomains) to incorporate the
identified extracellularly located LRP5 mutations. Separate models were vi-
sualized for analysis of structural effects by YASARA.
Immunohistochemistry Studies. Formalin-fixed paraffin-embedded liver cyst
tissue from proband III/18, four unrelated PCLD patients with PRKCSH c.1341–
2A > G mutations, and normal human liver tissue were available for im-
munohistochemistry studies. Staining intensity for the presence of LRP5 was
compared between LPR5 and PRKCSH mutants.
Expression Constructs. Total RNA was isolated from liver tissue using TRIzol
Reagent (Invitrogen), and oligodT cDNAwas obtained by RT Transcriptor First
Strand cDNA synthesis kit (Roche Applied Sciences). Full-length WT LRP5 was
obtained using the Faststart High Fidelity PCR System (Roche). LRP5 was
cloned into the mammalian expression vector pcDNA3.1_V5_His TOPO-TA
(Invitrogen) and checked by Sanger sequencing. An extracellularly c.3562C >
T (p.R1188W) and an intracellularly located c.4651G > A (p.D1551N) LRP5
construct were generated by mutating the pcDNA.LRP5.WT vector using the
Quick Change-II-XL Site-Directed Mutagenesis Kit (Agilent Technologies).
Luciferase Activity Assays.We used three cell lines to assess the functional effects
of WT and mutant LRP5. For the activity assay, 5.0 × 103 CHO cells, 5.0 × 103











HEK293 cells, and 5.0 × 103 human cholangiocyte 69 (H69) cells per well were
seeded in a 96-well plate in triplicate. After 24 h, cells were transiently
transfected using X-tremeGeneHD (Roche) with 100 ng LRP5 construct
(LRP5WT; LRP5R1188W; LRP5D1551N) or empty vector and 100 ng of TCF/LEF1
Reporter or 100 ng negative control according to the manufacturers’
instructions (Cignal TCF/LEF1 Reporter Assay Kit; Qiagen). Sixteen hours after
transfection, medium was replaced by medium with or without 250 ng/mL
human Wnt3a (5036-WN; R&D Systems) to initiate Wnt signaling. Cells were
cultured for another 24 h, and luciferase activity was detected using the
Dual-Glo Luciferase Assay System (Cat. No. E2920; Promega) in an Infin-
iteM200-Pro plate reader (Tecan). Firefly luciferase activity was normalized
to Renilla luciferase activity for variations in transfection efficiencies. Values
are reported as means ± SD. These experiments were conducted in triplicate
and performed three times. Western blotting was also performed to analyze
possible differences in expression levels between the WT and mutant LRP5.
qPCR. We conducted transient transfections of HEK293 cells with LRP5 con-
structs as previously described. The signaling was activated by addition of
Wnt3a for 24 h. Total RNA was extracted with TRIzol (Invitrogen). Template
cDNA was obtained using the iScript cDNA synthesis kit (Biorad). Expression
levels of Wnt target genes were assessed twice by qPCR experiments (in
triplicate) using the CFX96 real-time detection system (Biorad).
Immunofluorescence Imaging. A total of 4.0 × 104 CHO cells per well were
seeded on poly-L-lysine–coated Ø12-mm cover glasses on a 24-well plate and
transiently transfected with 100 ng of LRP5WT or mutant LRP5 construct.
After 24 h, medium was refreshed, and cells were cultured for another 24 h
followed by paraformaldehyde fixation and immunofluorescence staining.
Statistics.Groups were compared using descriptive statistics and compared by
the Student t test. Both groups were compared by using the nonparametric
Mann–Whitney U test. P < 0.05 was considered statistically significant. All
analyses were calculated by SPSS software v18.0.
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